Cargando…

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma

A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellegrini, Cinzia, Broccoli, Alessandro, Pulsoni, Alessandro, Rigacci, Luigi, Patti, Caterina, Gini, Guido, Mannina, Donato, Tani, Monica, Rusconi, Chiara, Romano, Alessandra, Vanazzi, Anna, Botto, Barbara, Santoro, Armando, Hoaus, Stefan, Rigolin, Gian Matteo, Musto, Pellegrino, Mazza, Patrizio, Molica, Stefano, Corradini, Paolo, Fama, Angelo, Gaudio, Francesco, Merli, Michele, Ronconi, Fioravante, Gritti, Giuseppe, Vallisa, Daniele, Tosi, Patrizia, Liberati, Anna Marina, Pinto, Antonello, Pavone, Vincenzo, Gherlinzoni, Filippo, Bianchi, Maria Paola, Volpetti, Stefano, Trentin, Livio, Goldaniga, Maria Cecilia, Bonfichi, Maurizio, De Renzo, Amalia, Schiavotto, Corrado, Spina, Michele, Carella, Angelo Michele, Stefoni, Vittorio, Argnani, Lisa, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710959/
https://www.ncbi.nlm.nih.gov/pubmed/29207679
http://dx.doi.org/10.18632/oncotarget.18114
_version_ 1783282979345268736
author Pellegrini, Cinzia
Broccoli, Alessandro
Pulsoni, Alessandro
Rigacci, Luigi
Patti, Caterina
Gini, Guido
Mannina, Donato
Tani, Monica
Rusconi, Chiara
Romano, Alessandra
Vanazzi, Anna
Botto, Barbara
Santoro, Armando
Hoaus, Stefan
Rigolin, Gian Matteo
Musto, Pellegrino
Mazza, Patrizio
Molica, Stefano
Corradini, Paolo
Fama, Angelo
Gaudio, Francesco
Merli, Michele
Ronconi, Fioravante
Gritti, Giuseppe
Vallisa, Daniele
Tosi, Patrizia
Liberati, Anna Marina
Pinto, Antonello
Pavone, Vincenzo
Gherlinzoni, Filippo
Bianchi, Maria Paola
Volpetti, Stefano
Trentin, Livio
Goldaniga, Maria Cecilia
Bonfichi, Maurizio
De Renzo, Amalia
Schiavotto, Corrado
Spina, Michele
Carella, Angelo Michele
Stefoni, Vittorio
Argnani, Lisa
Zinzani, Pier Luigi
author_facet Pellegrini, Cinzia
Broccoli, Alessandro
Pulsoni, Alessandro
Rigacci, Luigi
Patti, Caterina
Gini, Guido
Mannina, Donato
Tani, Monica
Rusconi, Chiara
Romano, Alessandra
Vanazzi, Anna
Botto, Barbara
Santoro, Armando
Hoaus, Stefan
Rigolin, Gian Matteo
Musto, Pellegrino
Mazza, Patrizio
Molica, Stefano
Corradini, Paolo
Fama, Angelo
Gaudio, Francesco
Merli, Michele
Ronconi, Fioravante
Gritti, Giuseppe
Vallisa, Daniele
Tosi, Patrizia
Liberati, Anna Marina
Pinto, Antonello
Pavone, Vincenzo
Gherlinzoni, Filippo
Bianchi, Maria Paola
Volpetti, Stefano
Trentin, Livio
Goldaniga, Maria Cecilia
Bonfichi, Maurizio
De Renzo, Amalia
Schiavotto, Corrado
Spina, Michele
Carella, Angelo Michele
Stefoni, Vittorio
Argnani, Lisa
Zinzani, Pier Luigi
author_sort Pellegrini, Cinzia
collection PubMed
description A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.
format Online
Article
Text
id pubmed-5710959
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57109592017-12-04 Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma Pellegrini, Cinzia Broccoli, Alessandro Pulsoni, Alessandro Rigacci, Luigi Patti, Caterina Gini, Guido Mannina, Donato Tani, Monica Rusconi, Chiara Romano, Alessandra Vanazzi, Anna Botto, Barbara Santoro, Armando Hoaus, Stefan Rigolin, Gian Matteo Musto, Pellegrino Mazza, Patrizio Molica, Stefano Corradini, Paolo Fama, Angelo Gaudio, Francesco Merli, Michele Ronconi, Fioravante Gritti, Giuseppe Vallisa, Daniele Tosi, Patrizia Liberati, Anna Marina Pinto, Antonello Pavone, Vincenzo Gherlinzoni, Filippo Bianchi, Maria Paola Volpetti, Stefano Trentin, Livio Goldaniga, Maria Cecilia Bonfichi, Maurizio De Renzo, Amalia Schiavotto, Corrado Spina, Michele Carella, Angelo Michele Stefoni, Vittorio Argnani, Lisa Zinzani, Pier Luigi Oncotarget Clinical Research Paper A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin’s lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients. Impact Journals LLC 2017-05-23 /pmc/articles/PMC5710959/ /pubmed/29207679 http://dx.doi.org/10.18632/oncotarget.18114 Text en Copyright: © 2017 Pellegrini et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Pellegrini, Cinzia
Broccoli, Alessandro
Pulsoni, Alessandro
Rigacci, Luigi
Patti, Caterina
Gini, Guido
Mannina, Donato
Tani, Monica
Rusconi, Chiara
Romano, Alessandra
Vanazzi, Anna
Botto, Barbara
Santoro, Armando
Hoaus, Stefan
Rigolin, Gian Matteo
Musto, Pellegrino
Mazza, Patrizio
Molica, Stefano
Corradini, Paolo
Fama, Angelo
Gaudio, Francesco
Merli, Michele
Ronconi, Fioravante
Gritti, Giuseppe
Vallisa, Daniele
Tosi, Patrizia
Liberati, Anna Marina
Pinto, Antonello
Pavone, Vincenzo
Gherlinzoni, Filippo
Bianchi, Maria Paola
Volpetti, Stefano
Trentin, Livio
Goldaniga, Maria Cecilia
Bonfichi, Maurizio
De Renzo, Amalia
Schiavotto, Corrado
Spina, Michele
Carella, Angelo Michele
Stefoni, Vittorio
Argnani, Lisa
Zinzani, Pier Luigi
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title_full Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title_fullStr Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title_full_unstemmed Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title_short Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
title_sort italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory hodgkin’s lymphoma
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710959/
https://www.ncbi.nlm.nih.gov/pubmed/29207679
http://dx.doi.org/10.18632/oncotarget.18114
work_keys_str_mv AT pellegrinicinzia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT broccolialessandro italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT pulsonialessandro italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT rigacciluigi italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT patticaterina italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT giniguido italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT manninadonato italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT tanimonica italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT rusconichiara italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT romanoalessandra italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT vanazzianna italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT bottobarbara italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT santoroarmando italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT hoausstefan italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT rigolingianmatteo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT mustopellegrino italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT mazzapatrizio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT molicastefano italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT corradinipaolo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT famaangelo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT gaudiofrancesco italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT merlimichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT ronconifioravante italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT grittigiuseppe italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT vallisadaniele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT tosipatrizia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT liberatiannamarina italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT pintoantonello italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT pavonevincenzo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT gherlinzonifilippo italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT bianchimariapaola italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT volpettistefano italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT trentinlivio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT goldanigamariacecilia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT bonfichimaurizio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT derenzoamalia italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT schiavottocorrado italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT spinamichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT carellaangelomichele italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT stefonivittorio italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT argnanilisa italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma
AT zinzanipierluigi italianreallifeexperiencewithbrentuximabvedotinresultsofalargeobservationalstudyon234relapsedrefractoryhodgkinslymphoma